Infectious Disease Nucleic Acid Testing

Aug 09, 2011, 04:51 ET from Reportlinker

NEW YORK, Aug. 9, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Infectious Disease Nucleic Acid Testing

http://www.reportlinker.com/p0591342/Infectious-Disease-Nucleic-Acid-Testing.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

This 360-page report presents an overview of the clinical significance and market needs for major infectious diseases, as well as extensive listings of companies developing and marketing molecular diagnostic technologies and products.

Contains 360 pages and 20 tables

Table of Contents

1. Overview

2. Major Infectious Diseases

AIDS

Structure and Composition

Classification

AIDS Origins

Animal Lentivirus Systems

Virus Receptors

HIV Infections in Humans

Pathogenesis and Pathology

CD4T Lymphocytes and Memory Cells

Monocytes and Macrophages

Lymphoid Organs

Neural Cells

Viral Coinfections

Clinical Findings

Plasma Viral Load

Pediatric AIDS

Neurologic Disease

Opportunistic Infections

Cancer

Immunity

Laboratory Diagnosis

Virus Isolation

Serology

Viral Nucleic Acid/Antigen Detection

Epidemiology

Worldwide Spread of AIDS

United States

Routes of Transmission

Prevention, Treatment, And Control

Antiviral Drugs

Vaccines

Transmission HIV in Blood Products

HIV Transmission in Transplant and Artificial Insemination Recipients

Diagnostic Tests

Enzyme Immunoassay Interpretation

Specificity, Sensitivity and Predictive

Value

Competition Assays

Western Blot Technique

ImmunoFluorescence Assays (IFA)

Radioimmunoprecipitation

HIV1/HIV2 Combination Testing

Methods of HIVAntigen Detection

Antigen Assays and Blood Screening

Urine Tests

DNA Probes

Overview

Quantitative PCR

In Situ PCR

Needed Improvements

Viral Load/Drug Resistance Testing

Genotype and Phenotype Testing

Blood Banking Considerations

Adenovirus

Background

Diagnostic Tests

Vaccines and Drugs

AdenoAssociated Viruses (AAV)

Anthrax/Bacillus Anthracis

Background

Diagnostic Tests

Vaccines and Drugs

Babesiosis

Background

BEA and Other Bartonella Diseases

Background

Diagnostic Tests

Vaccines and Drugs

Chagas Disease

Background

Campylobacter

Background

Diagnostic Tests

Culture Identification

Vaccines and Drugs

Chlamydia

Background

Chlamydia psittaci

Chlmaydia pneumoniae

Chlamydia trachomatis

Diagnostic Tests

Vaccines and Drugs

CreutzfeldtJakob's Disease

Background

Blood Transmission

Diagnostic Tests

Major Commercial and Academic Players

Bayer

Disease Sciences/Bio Tec Global

Imperial College School of Medicine

OrthoClinical Diagnostics

Pall

ProMetic Life Sciences

Proteome Sciences/Idexx

QOne Biotech

Serono

U.S. Agricultural Research Service

Drugs

Vaccines

Cytomegalovirus

Background

Chorioretinitis

Gastrointestinal

Central Nervous System Disease

Diagnostic Tests

Vaccines and Drugs

Ebola Virus

Background

Epidemiology

Clinical Syndromes

Diagnostic Tests

Vaccines and Drugs

EchoVirus

Background

Acute Aseptic Meningitisis

Encephalitis

Exanthems

Respiratory Disease

Myopericarditis

Neonatal Infections

Diagnostic Tests

Vaccines and Drugs

Encephalitis

Background

Diagnostic Tests

Vaccines and Drugs

Enteroviruses

Background

Diagnostic Tests

Viral Isolation and Identification

Antibody Tests

Vaccines and Drugs

EpsteinBarr Virus

Background

Diagnostic Tests

Vaccines and Drugs

Gonorrhea

Background

Diagnostic Tests

Vaccines and Drugs

Hepatitis

Hepatitis A

Hepatitis B

Structure and Composition

Replication

Hepatitis C

Hepatitis D (Delta)

Hepatitis E

Hepatitis G

Hepatitis Infections Pathology

Clinical Findings

Laboratory Tests

Hepatitis A

Hepatitis B

Hepatitis C

Hepatitis D

Hepatitis E

VirusHost Immune Reactions

Epidemiology

Hepatitis A

Hepatitis B

Hepatitis C

Hepatitis D (Delta)

Vaccines and Drugs

Herpes Simplex Virus

Background

Diagnostic Tests

Vaccines and Drugs

Legionella

Background

Diagnostic Tests

Vaccines and Drugs

Lyme Disease

Background

Clinical Description

Clinical Case Definition

Laboratory Criteria for Diagnosis

Case Classification

Diagnostic Tests

Vaccines and Drugs

Malaria

Mycoplasma

Background

Ureaplasma Urealyticum & Mycoplasma

Hominis

Diagnostic Tests

Vaccines and Drugs

Papillomaviruses/HPV

Background

HPV in Cancer

Cervical Neoplasm

Diagnostic Tests

Vaccines and Drugs

Prevention

Parvovirus B19

Background

Microbiology

Epidemiology

Clinical Syndromes

Erythema Infectiosum (Slapped Cheek)

Adult Polyarthropathy

Transient Aplastic Crisis

Transient Pancytopenia

Red Cell Aplasia in Immunocompromised

Perinatal Infections

Diagnostic Test

Vaccines and Drugs

Pneumonia

Background

Diagnostic Tests

Vaccines and Drugs

Polyomaviruses

Background

Diagnostic Tests

Vaccines and Drugs

Salmonellosis

Background

Diagnostic Tests

Vaccines and Drugs

Shigellosis

Background

Diagnostic Tests

Vaccines and Drugs

Streptococci

Background

Diagnostic Tests

Vaccines and Drugs

Group A Streptococci

Group B Streptococci

Toxoplasmosis

Background

Diagnostic Tests

Vaccines and Drugs

Tuberculosis

Background

Diagnostic Tests

Microscopic Characteristics

Cultural Characteristics

Skin Tests

MDRTB

Vaccines and Drugs

West Nile Virus

Background

Clinical Syndromes

Diagnostic Tests

Vaccines and Drugs

Yersinia

Background

Diagnostic Tests

Vaccines and Drugs

3. Antibiotic Susceptibility

List of Tables

Table 1: Major Companies Developing or Marketing AIDS NAT and other Direct Identification Tests

Table 2: Major Companies Developing or Marketing Adenovirus NAT and other Direct Identification Tests

Table 3: Major Companies Developing or Marketing Campylobacter NAT and ther Direct Identification Tests

Table 4: Major Companies Developing or Marketing Chlamydia NAT and other Direct Identification Tests

Table 5: Major Companies Developing or Marketing CMV NAT and other Direct Identification Tests

Table 6: Major Companies Developing or Marketing EBV NAT and other Direct Identification Tests

Table 7: Major Companies Developing or Marketing Gonorrhea NAT and other Direct Identification Tests

Table 8: Major Companies Developing or Marketing Hepatitis NAT and other Direct Identification Tests

Table 9: Major Companies Developing or Marketing Herpes NAT and other Direct Identification Tests

Table 10: Major Companies Developing or Marketing Legionella NAT and other Direct Identification Tests

Table 11: Major Companies Developing or Marketing Lyme Disease NAT and ther Direct Identification Tests

Table 12: Major Companies Developing or Marketing Mycoplasma NAT and other Direct Identification Tests

Table 13: Major Companies Developing or Marketing Papilloma Virus NAT and ther Direct Identification Tests

Table 14: Major Companies Developing or Marketing Pneumonia NAT and other Direct Identification Tests

Table 15: Major Companies Developing or Marketing Salmonella NAT and other Direct Identification Tests

Table 16: Major Companies Developing or Marketing Shigella NAT and other Direct Identification Tests

Table 17: Major Companies Developing or Marketing Streptococci NAT and ther Direct Identification Tests

Table 18: Major Companies Developing or Marketing Toxoplasmosis NAT and ther Direct Identification Tests

Table 19: Major Companies Developing or Marketing Tuberculosis NAT and ther Direct Identification Tests

Table 20: Major Companies Developing or Marketing Cancer NAT Tests

Table 21: Major Companies Developing or Marketing NAT Test for Genetic Diseases

To order this report:

In Vitro Diagnostic Industry: Infectious Disease Nucleic Acid Testing

In Vitro Diagnostic Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com